Cipla has launched Afrezza inhaled dry powder insulin for the treatment of diabetes in adult patients in India, the company said. Cipla acquired the rights to market Afrezza in India from MannKind Corporation in 2018, and the Indian Central Drugs Standard Control Organization (CDSCO) approved the company’s marketing application for Afrezza in December 2024.
In the US, Afrezza has been approved for the treatment of diabetes in adults since 2014, and the FDA recently accepted MannKind’s sBLA for the use of Afrezza in pediatric diabetes patients.
Cipla Limited Global Chief Operating Officer Achin Gupta commented, “At Cipla, our purpose has always been simple: to make quality healthcare more accessible for every patient. The introduction of Afrezza in India reflects that responsibility. This innovation not only simplifies insulin delivery but also eases many of the emotional and practical barriers patients face with daily insulin injections. With our reach and our deep commitment to patient well-being, we hope to support millions of Indians in managing their diabetes with greater confidence and comfort.”
Read the Cipla press release
